The findings come from the first and only decentralized real-world study examining how HD chorea affects patients and caregivers and how treatment impacts quality of life
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
Bolstering neuroscience push with late-stage Tourette therapy
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
The agreement could rise to $900 million if key commercial milestones are met
The online platform is designed to go beyond clinical treatment, offering practical tools, lived-experience insights, and peer-informed support intended to reduce isolation and improve day-to-day coping
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
